Acesion Pharma, a Copenhagen, Denmark-based biotech company pioneering first-in-class novel therapies for atrial fibrillation (‘AF’), closed a €45M Series B financing round.
The financing was co-led by Canaan and Alpha Wave with participation from the Global BioAccess Fund, as well as existing investor Novo Holdings. In connection with the closing of the financing, the composition of the Acesion board of directors will change to include Tim Shannon, General Partner at Canaan, and Nik Economopoulos, Analyst from Alpha Wave. Jørgen Søberg Petersen, Partner at Novo Holdings, will remain Chairman.
The company intends to use the funds to advance the clinical development of AP31969, an SK ion channel inhibitor optimised for chronic oral treatment of AF. Earlier this year, Acesion demonstrated clinical proof-of-concept with AP30663, its first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm.
AP31969 will be developed for chronic oral maintenance treatment to prevent AF recurrence. Following the Series B financing, the company is capitalised to progress AP31969 into a phase 1 and completion of a phase 2 trial.
Led by Anders Gaarsdal Holst, MD, PhD, Chief Executive Officer, Acesion is able to identify and progress SK channel inhibitors into clinical trials. Its AP30663 IV is a short acting conversion therapy for hospitals that has completed a phase 2 trial proving the value of this first-in-class mechanism in AF and thereby de-risking Acesion’s broader SK inhibitor pipeline.
FinSMEs
26/09/2023